PDL BioPharma (PDLI) Reports Q2 EPS of $0.39
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
PDL BioPharma Announces Second Quarter 2017 Financial Results
August 3, 2017 4:02 PM EDTINCLINE VILLAGE, Nev., Aug. 3, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the second quarter ended June 30, 2017 including:
Total revenues of $143.8 million and $189.3 million for the three and six months ended June 30, 2017, respectively. GAAP diluted EPS of $0.39 and $0.42 for the three and six months ended June 30, 2017, respectively. GAAP net income attributable to PDL's shareholders of $60.4 million and $67.7 million for the three and six months ended June 30, 2017, respectively. Non-GAAP net income attributable to PDL's shareholders of $40.2... More